A smartphone is “a mobile phone that performs many of the functions of a computer, typically having a touchscreen interface, internet access, and an operating system capable of running downloaded apps” [1]. Global smartphone penetration continues to rise rapidly due to their increasing value and utility, their ease of use and their increasing affordability.
Due to the increasing miniaturisation of sensors and circuitry, smartphones have been able to leverage multiple inbuilt sensors to enhance user experience and provide other features. For example, tri-axial accelerometers are useful in determining the spatial positioning of the smartphone and thus enabling the screen to re-orientate when the handset is rotated, and proximity sensors are used to switch off screen controls when the handset is held to the face during a phone call.
More recently, novel application of these inbuilt sensors has enabled new and inventive uses for the smartphone in the area of health and wellness. In more recent operating system releases, AppleTM Inc., for example, have provided a health app with the iPhoneTM which, amongst other things, collects activity data from the smartphone accelerometer – measuring elements such as the number of steps, walking distance and flights climbed based on the tri-axial accelerometer measurements recorded whilst the phone is being carried in a pocket, bag or in the hand of the owner [2].
Because of the proliferation of sensors and components contained in modern smartphones, and the ability to develop apps that can access sensor readings by leveraging the open development capabilities of the main platforms, we have arrived at an exciting inflexion point in our ability to use the increasingly ubiquitous smartphone as a platform to measure a variety of novel health-related endpoints that may have value in clinical trials.
There are a growing number of scientific studies exploring the use of smartphone sensors to provide outcomes measures traditionally recorded by research grade devices, clinician subjective ratings or by other methodologies.
Milani et al. [4], for example, reported a literature review of smartphone apps that evaluate the range of motion and/or the angular measurement relating to various joint movements in patients with a range of conditions. Examples reported included the use of the smartphone accelerometers and gyroscopes to measure knee range of motion [5]; cervical spine mobility [6], and the angle of trunk rotation during a forward bend test [7,8].
The extent of shoulder rotation using a smartphone gyroscope has been reported by El-Zayat et al. [9]; and researchers from the Republic of Korea similarly used a similar approach to measure the range of motion of the shoulder in subjects suffering from unilateral symptomatic shoulder. They found that the smartphone gyroscope sensor results showed acceptable reliability and fairly high correlation with manual goniometer readings [10].
The iPhone magnometer has also been used to measure the cervical range of motion on the horizontal plane using an iPhone placed on the head of the subject during a clinical assessment by an investigator [6]. Another investigator app, Dr Goniometer, measures flexion of the elbow and knee using a virtual goniometer that is visible on the smartphone screen during camera use [11, 12].
In addition to range of motion, accelerometers are valuable in measuring gait and balance. Kosse et al. [13] performed a validation study in which they compared the gait and posture measurement capabilities of the iPod TouchTM with that obtained simultaneously using a research grade accelerometer, the DynaPortTM Hybrid (McRoberts BV, The Hague, The Netherlands).
The study, conducted in 60 healthy volunteers aged 18 – 75 years who performed walking and stationary balance tests, concluded that the iPod Touch was able to produce valid and reliable measures of gait and postural control. In a second study, Mellone et al. reported that the accelerometer in an Android smartphone (the HTC DesireTM) provided consistent results compared to the DynaPort Hybrid accelerometer when evaluating the Timed Up and Go (TUG) test [14].
Other researchers have used the accelerometer and gyroscope signals from an iPhone mounted on a specially designed glove enabling it to rest on the back of the hand to measure tremor in Parkinson’s Disease (PD) patients during a seated test in which patients kept their hands in their lap [15, 16].
This approach has also been applied by Roche Pharmaceuticals in their development of an Android app to assess tremor associated with PD using two tremor tests – a resting test where the smartphone is held with the hand resting in the lap while seated, and a postural tremor test where tremor is measured while the smartphone is held in the hand with the arm outstretched [17]. This app is currently being used in a phase 1 trial and also includes other short active tests including a phonation test, a balance test, a 20m walk test measuring aspects of gait, and a dexterity test where the user is instructed to tap two buttons alternately on the touchscreen.
In addition to dexterity tests, as described above, touchscreens also provide the ability to measure aspects of cognitive function. Numerous examples of brain training apps exist in the health and wellness industry, and in clinical research a number of standard tests have been adapted for use on smartphones, where the touchscreen can be used to measure aspects of both the speed and the accuracy of task completion.
Apple Research Kit, for example, contains a number of examples of standard cognitive tests used in clinical research that have been adapted for use on the iPhone, including the spatial memory test, the paced auditory/visual serial addition test (PVSAT), and the simple reaction time test [18]. ICON has experience of using the PVSAT through Apple Research Kit in a study of 155 patients suffering form conditions causing chronic pain [19].
Within an interactive game environment, the Project:EVO app is used to measure interference processing, a key component of executive function. This smartphone game is currently being tested in a variety of clinical studies and patient populations including ADHD, autism, depression, and traumatic brain injury. Pfizer, for example, has recently funded a study to determine if the game can be used as a biomarker to enable the selection and longitudinal assessment of Alzheimer’s patients in clinical trials [20].
Shire is also funding investigations on the use of the game in ADHD clinical trials. Voice acoustic measures have been shown to be sensitive indicators of disease severity and therapeutic response in many CNS disorders, including Parkinson's disease, depression, and schizophrenia [21]. Analysis of uninterrupted speech samples in depressed patients have shown good correlation with clinician ratings [22].
Aspects such as speaking rate and pitch variation have been shown to be well correlated with the total Hamilton Depression Rating Scale score, where it is observed that speech slows and becomes more monotonic with increasing severity of depression [23]. Similarly, voice acoustics endpoints have been shown to have value in assessment of voice and speech disorders in PD [24], which often present as an early indicator of the disease.
The availability of the smartphone microphone to record sound files facilitates easy collection of data for voice analysis from patients in the home or clinic settings. For example, a phonation test has been used in the mPower app developed by Sage Bionetworks and the University of Rochester [25], in which users were instructed maintain sustained phonation at a comfortable pitch and loudness, and to keep this note constant for as long as possible by, for example, holding the sound “ahh”.
Analysis of this sound file in PD subjects might include, for example, calculation of summary measures such as the fundamental frequency (pitch), jitter (the extent of variation of the voice range) and shimmer (the extent of variation of expiratory flow). Smartphone microphones have also been used to develop stethoscope apps [26].
The smartphone camera has the potential to be a valuable component for use in clinical trials. The potential of taking and recording quality photographs pertinent to a medical condition means that participants in clinical trials may be able to provide much richer data about their conditions than previously possible form the home setting. Examples might include psoriasis and other dermatological conditions, wound healing, injection site reactions and melanoma.
A recent addition to the Apple store, and built using Apple Research Kit, the Mole Mapper app developed by Oregon Health & Science University and Sage Bionetworks, uses photography to track changes in moles over time, providing a resource that can be shared with physicians [27]. Accessories that can be attached to the smartphone camera provide additional possibilities.
Cellscope Inc. (San Francisco, California) have developed an iPhone attachment that fits over the iPhone rear camera to create an otoscope with the added advantage that images and videos of the ear examination can be recorded. The smartphone camera and light-emitting diode light has successfully shown to accurately measure heart rate when the index finger is pressed against the rear camera when compared to the Nonin 9560BT pulse oximeter (Nonin Medical Inc., Plymouth, Minnesota) [28].
Artificial intelligence approaches take the use of the smartphone camera to another level. A new app built using Apple Research Kit uses the FaceTime HD camera in the iPhone along with innovative facial recognition algorithms to analyse a child’s emotional reaction whilst watching a short series of videos [29].
Developed by Duke University, Peking University and the University of Cape Town, this approach is being evaluated to determine whether video technology can detect emotional and developmental problems in children as young as 18 months, with an aim to providing a means to screen children in their homes for autism and other developmental challenges.
The potential of leveraging smartphone sensors to collect novel health outcomes measures and derive new study endpoints is huge. New development s on the main platforms have facilitated this, such as Apple ResearchKit [30] and Android ResearchStack [31]. More work will need to be done to provide the evidence required to support the use of these health outcomes and endpoints collected in this way, in particular understanding the reliability and validity of data collected in this way.
References:
[1] Oxford English Dictionary (2016). http://www.oxforddictionaries.com/
[2] Apple Inc. (2015). Health: An innovative new way to use your health and fitness information. http://www.apple.com/uk/ios/health/
[3] Byrom B. et al. (2016). A Review Evaluating the Validity of Smartphone Sensors and Components to Measure Clinical Outcomes in Clinical Research. ISPOR 21st Annual International Meeting, May 2016.
[4] Milani, P., Coccetta, C.A., Rabini, A. et al. (2014). Mobile Smartphone Applications for Body Position Measurement in Rehabilitation: A Review of Goniometric Tools. Physical Medicine and Rehabilitation; 6: 1038-1043.
[5] Jenny, J.Y. (2013). Measurement of the knee flexion angle with a smartphone application is precise and accurate. J Arthroplasty;28: 784-787.
[6] Tousignant-Laflamme, Y., Boutin, N., Dion, A.M., et al. (2013). Reliability and criterion validity of two applications of the iPhone to measure cervical range of motion in healthy participants. J Neuroeng Rehabil.; 10:69-77.
[7] Izatt, M.T., Bateman, G.R., Adam, C.J. (2012). Evaluation of the iPhone with an acrylic sleeve versus the Scoliometer for rib hump measurement in scoliosis. Scoliosis; 7:14-20.
[8] Franko, O.I., Bray, C., Newton, P.O. (2012). Validation of a scoliometer smartphone app to assess scoliosis. J Pediatr Orthop; 32: e72-e75.
[9] El-Zayat, B.F., Efe, T., Heidrich, T., et al. (2011). Objective assessment of shoulder mobility with a new 3D gyroscope – a validation study. BMC Musculoskelet Disord; 12: 168-176.
[10] Shin, S.H., Ro, D.H., Lee, O-S. et al. (2012). Within-day reliability of shoulder range of motion measurement with a smartphone. Manual Therapy; 17: 298–304.
[11] Ferriero, G., Sartorio, F., Foti, C., et al. (2011). Reliability of a new application for smartphones (DrGoniometer) for elbow angle measurement. Physical Medicine and Rehabilitation; 3: 1153-1154.
[12] Ferriero, G., Vercelli, S., Sartorio, F., et al. (2013). Reliability of a smartphone-based goniometer for knee joint goniometry. Int J Rehabil Res; 36: 146-151.
[13] Kosse, N.M., Caljouw, S., Vervoort, D. et al. (2015). Validity and Reliability of Gait and Postural Control Analysis Using the Tri-axial Accelerometer of the iPod Touch. Annals of Biomedical Engineering; 43(8): 1935–1946.
[14] Mellone, S., Tacconi, C., Chiari, L. (2012). Validity of a Smartphone-based instrumented Timed Up and Go. Gait & Posture; 36: 163–165.
[15] Kostikis, N., Hristu-Varsakelis, D., Arnaoutoglou, M., et al. (2011). “Towards remote evaluation of movement disorders via smartphones,” in Proc. Engineering in Medicine and Biology Society (EMBC), 33rd Annual International Conference of the IEEE, pp. 5240–5243.
[16] Kostikis, N., Hristu-Varsakelis, D., Arnaoutoglou, M., et al. (2014). “Smartphone-based Evaluation of Parkinsonian Hand Tremor: Quantitative Measurements vs Clinical Assessment Scores,” in Proc. Engineering in Medicine and Biology Society (EMBC), 36th Annual International Conference of the IEEE, pp. 906-909.
[17] http://www.roche.com/media/store/roche_stories/roche-stories-2015-08-10.htm
[18] Apple Inc. (2016). Research Kit Active Tasks. http://researchkit.org/docs/docs/ActiveTasks/ActiveTasks.html
[19] Byrom, B. et al. (2017). Applicability of Apple Research Kit to Deliver Cognitive Testing in Clinical Trials: Results of a Pilot Study. ISPOR 22nd Annual International Meeting, May 2017.
[20] Akili Interactive Labs (2014). “Akili Interactive Labs announces partnership with Pfizer to test video game in people at risk of Alzheimer's disease,” http://www.prnewswire.com/news-releases/akili-interactive-labs-announces-partnership-with-pfizer-to-test-video-game-in-people-at-risk-of-alzheimers-disease-239412291.html.
[21] Byrom, B. (2006). Innovative ePRO: Tapping into the Potential. Applied Clinical Trials; June: 64-72.
[22] Mundt, J.C., Snyder, P.J, Cannizzaro, M.S., et al. (2007). Voice acoustic measures of depression severity and treatment response collected via interactive voice response (IVR) technology. J. Neurolingusitics; 20(1): 50-64.
[23] Cannizzaro, M., Harel, B., Reilly, N., et al. (2004). Voice Acoustical Measurement of the Severity of Major Depression. Brain and Cognition; 56: 30-35.
[24] Rusz, J., Čmejla, R., Růžičková, H., et al. (2011). Acoustic Assessment of Voice and Speech Disorders in Parkinson’s Disease Through Quick Vocal Test. Mov Disord.; 26(10): 1951-1952.
[25] Sage Bionetworks. (2015). Parkinson’s mPower Study App. https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewSoftware?id=972191200&mt=8&ls=1&v0=www-us-researchkit-itms-mpower
[26] Yoo, J.H. (2013). The meaning of information technology (IT) mobile devices to me, the infectious disease physician. Infect Chemother.; 45(2): 244–251.
[27] Sage Bionetworks. (2015). Mole Mapper Melanoma Study App. https://itunes.apple.com/us/app/mole-mapper-melanoma-study/id1048337814?mt=8
[28] Gregowski, M.J., Mueller, M., Vertegel, A. et al. (2012). Development and validation of a smartphone heart rate acquisition application for health promotion and wellness telehealth applications. Int J Telemed Appl. 2012:696324.
[29] Duke Medicine. (2015). Autism & Beyond. https://itunes.apple.com/us/app/autism-beyond/id1025327516?mt=8
[30] Apple Inc. (2016). https://www.apple.com/uk/researchkit/
[31] Android ResearchStack (2017). http://researchstack.org/
In this section
-
Digital Disruption
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
-
Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Flexible delivery models
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel